A comparative analysis of the clinical efficacy of cholinergic drugs and acetylcholinesterase inhibitors (IHE), as well as their combination, in the treatment of cerebrovascular disease and consequences of intracranial injury according to clinical, instrumental and laboratory dynamic observations. Ninety patients with cerebrovascular pathology, including 45 with chronic brain ischemia stage 2 (ICD-10 I67) and 45 with sequelae of intracranial injury (ICD-10 T90.5), were enrolled in the study. Complex treatment of patients included basic and specific therapy. The groups were divided into 3 subgroups of 15 people: the neuromidin group, the gliatilin group and the neuromidin + gliatilin group. The duration of treatment was 2 months. All patients underwent a comprehensive clinical, neurophysiological and laboratory examination prior to therapy, after 1 month and 2 month from the beginning of therapy: a study of cholinesterase activity in the blood, testing on MMSE and Hamilton scales, transcranial magnetic stimulation with determination of Central motor conduction time and somatosensory evoked potentials with calculation of Central afferent conduction time. Prior to treatment, a significant positive strong correlation was found between the age of patients and the level of CE activity in serum (Rs=0.77; p=0.0001). The treatment resulted in a significant (p<0.05) improvement of all parameters (except for MMSE that showed a trend towards improvement) in the neuromidin and the neuromidin + gliatilin subgroups of each group compared to those in the gliatilin subgroups. In addition, after 2 months from the beginning of treatment, there was a significant decrease in the activity of CE in serum in the neuromidin and the neuromidin + gliatilin subgroups. The study of deviations of the 'cholinergic profile' (the level of CE activity in the blood) in patients with cerebral pathology and the strategy using cholinergic drugs, IHE and their combination for the treatment of neuropsychiatric disorders, is one of the important directions in the optimization of combined therapy of patients of this profile.
22 November 2020 in Neuroscience and Behavioral Physiology
Phantom limb pain is a specific entity of neuropathic pain that develops in 30%85% of patients with amputated limbs and leads to considerable worsening of the quality of life. The number of such cases increases during military conflicts. It can be caused by a traumatic amputation due to mine blast injury, peculiarities of provided medical assistance, and the special psychological state of casualties being in extremely stressful situations at the moment of wounding. Phantom limb pain development is accompanied by multiple functional and structural changes at different levels of the peripheral and central nervous systems. As a result, different theories of pathogenesis are proposed. However, at present, no final opinion concerns mechanisms of phantom limb pain development. Although different versions of drug and non-drug therapy have been suggested, none of them turned out to be universal and fully effective. Many medications were found to be linked to phantom limb pain pathogenesis; however, even first-line therapy drugs (non-steroidal anti-inflammatory drugs, tricyclic antidepressants, narcotic analgesics, and anticonvulsants) often fail to provide adequate analgesia. Long-term prescription of narcotic analgesics is at risk of the development of addictive disorders. Surgical interventions have not demonstrated their effectiveness as well. Thus, their use is justified only in the case of ineffective conservative treatment. Poor efficacy of conventional concepts of phantom limb pain treatment led to the use of new means such as botulinum toxin therapy, non-drug methods (psychotherapy, mirror therapy, biological feedback, virtual reality, acupuncture, massage, hypnosis, etc.). Thus, the search for original methods based on the development and introduction of new drug therapy schemes is imperative. A possible solution to this problem is not only creating absolutely new non-opioid analgesics but also using adjuvant therapeutic means in the multimodality schemes of analgesia. The latter promotes neurotransmission in the antinociceptive system and potentiates the effect of traditional analgesics.
RERussian Federation Ministry Of Defense; St. Petersburg S.M. Kirov Military Medical Academy (A Federal Government-Funded Military Educational Institution Of Higher Education)
Russian Federation Ministry Of Defense; St. Petersburg S.M. Kirov Military Medical Academy (A Federal Government-Funded Military Educational Institution Of Higher Education)
+3
Study Objective: To study the incidence and the structure of the postoperative cerebral dysfunction after open and endovascular aortic valve replacement surgery, and to identify the risk factors and the methods of prevention of postoperative cerebral dysfunction after the open aortic valve replacement surgery. Study Design: Prospective cohort study. Materials and Methods. The study involved 114 patients (92 men and 22 women) aged 67 [58; 76] years, who undergone elective aortic valve replacement surgery. All patients were divided into three groups: “open surgery” (n = 82), “cerebroprotection” (n = 16) and “X-ray surgery” (n = 16). In the “open surgery” and “cerebroprotection” groups, patients undergo open aortic valve replacement surgery with cardiopulmonary bypass, in the “X-ray surgery” group transcatheter aortic valve implantation is performed. In the “cerebroprotection” group patients additionally received the 1.5% solution of meglumine sodium succinate in the early postoperative period. Study Results. The postoperative cerebral dysfunction was diagnosed in 41.2% of patients, the incidence of the postoperative cerebral dysfunction did not differ in the study groups. In the group “cerebroprotection” there was a shorter duration of symptomatic delirium of the early postoperative period (p = 0.0441) compared with the group “open surgery”. We identified 18 risk factors for postoperative cerebral dysfunction and its clinical types and two cerebroprotective factors — a body mass index more than 25 kg/m2 and the use of the meglumine sodium succinate in the early postoperative period. Conclusion. Aortic valve replacement surgery is characterized by the high incidence of the postoperative cerebral dysfunction, further improvement of the methods of the perioperative cerebroprotection is required. Keywords: postoperative cerebral dysfunction, perioperative stroke, symptomatic delirium of the early postoperative period, postoperative cognitive dysfunction, perioperative cerebroprotection, aortic valve replacement.
1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Рассмотрено оказание помощи пациенту с болезнью Альцгеймера (БА) с точки зрения экосистемы, т.е. системного подхода, описывающего эффективное партнерство, сотрудничество и исследования пациентов с БА. Эффективность данной экосистемы возможна только при условии вовлечения в ее развитие всех заинтересованных в ней участников, включая пациентов, медицинских работников всех уровней, государственные органы, частные компании и организации пациентов. Неудовлетворенные потребности пациентов с БА в оказании медицинской помощи, уходе и информационной поддержке являются следствием барьеров в экосистеме БА. К ключевым барьерам для пациента следует отнести низкую осведомленность о заболевании и его стигматизация в обществе, отсутствие качественных эпидемиологических данных, сложности своевременной диагностики, недостаток программ профилактики, неготовность к проведению реабилитации пациента с БА большинства врачей и другие факторы. На основании анализа экосистемы БА и пути пациента выделено 10 основных направлений (стратегий), необходимых для формирования экосистемы: проведение исследований в области диагностики и эпидемиологии БА, создания и осуществления программы когнитивного здоровья, формирование правовой базы, повышение осведомленности населения, оптимизация маршрутизации пациента для своевременной диагностики, организация сети клиник/лабораторий памяти, создание регистра пациентов с деменцией, разработка цифровых решений и поддержка социальных проектов.
5 October 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Diagnosis and treatment of early forms of cognitive impairment: possibilities of influencing neuronal energy metabolism. Resolution of the Council of Experts.